Janssen Presents New Data from First Phase 3 Trial of a Single-Tablet Regimen in a Rapid Initiation Model of Care Demonstrating Safety and Efficacy with SYMTUZA ® through 48 Weeks

Source: Johnson and Johnson - Category: Pharmaceuticals Source Type: news
More News: Pharmaceuticals